LONDON, July 24 (Reuters) - European regulators on Fridayrecommended the use of a combination of Novartis's drugs Tafinlar and Mekinist for treating certain patients withmelanoma, boosting prospects for medicines acquired fromGlaxoSmithKline.
The Swiss drugmaker said the U.S. Food and DrugAdministration had also granted priority review for thecombination.
Recommendations for marketing approval by the EuropeanMedicines Agency's Committee for Medicinal Products for HumanUse are normally endorsed by the European Commission within acouple of months.
(Reporting by Ben Hirschler, editing by David Evans)